mCig Inc (OTCMKTS:MCIG) has reported an update for its Hemp project and the soon to be launched line of CBD products. The firm is a large company that serves the legalized cannabis market.
The company is focusing on the NYAacres project that is Industrial Hemp on 40 acres. This is a CBD concentrated organic type known as Cherry Wine. It aims to produce 55,000 pounds of flower that will be used in producing organic CBD oil.
Five fields on the certified organic farm are already planted are being closely monitored on a daily basis. So as to enhance production conditions, organic honey bees are being used for cross-pollination in addition to installing irrigation as back up. The hot and long sunny days, as well as the cool nights being experienced in the area, provide an ideal environment for the crop.
Getting into Hemp business
Three years ago, MCIG began selling Hemp/CBD products, but later it unveiled its own VITACBD brand. However, it sold the brand to a public firm after two years. After a while MCIG formed a partnership with the farm, thus, reentering the hemp market.
Since different sectors of the company have experienced growth, MCIG has decided to expand the CBD sector by launching a new line of hemp products. The new products consist of probiotic pet edibles, natural skin cosmetics, and whole spectrum tinctures. The firm seems to have all the pieces of the puzzle. It has a professionally ran hemp farm, a capable research and development team and a dedicated sales team.
MCIG has also revealed that its consulting and construction department has managed to bag another management deal with a Costa Mesa client. The move will bring the total number of contracts to three. The department will now supervise operations across Palm Springs, Sacramento and now Costa Mesa.
MCIG has a legal license to cultivate, manufacture and to supply cannabis products. Thus, it has commenced concept designs for the construction of its own facility in California.
BetterLife Pharma Inc (OTCMKTS:PVOTF) Readies Interferon Alpha-2b To Clear Caronavirus From The Airways Of Patients
BetterLife Pharma Inc (OTCMKTS:PVOTF) expects to publish results of the third-party study of the drug – Interferon Alpha-2b in the journal Frontiers of Immunology this Friday. The company has examined the effectiveness of Interferon Alpha-2b on seventy-seven Wuhan based patients infected with moderate to severe coronavirus during January 16 and February 20, 2020. According to the study, the drug can effectively clear the coronavirus from the airways of affected patients.
An unexplored and uncontrolled study is conducted on seventy-seven patients in Wuhan by administering arbidol (200 mg t.i.d.) or nebulized IFN-α2b (5 mU b.i.d.) or a combination of both. In the trial, temperature, serum cytokine levels, blood chemistry, cell counts, and blood oxygen saturation levels are recorded. Interferon Alpha-2b has effectively reduced coronavirus duration either with or without arbidol in the upper respiratory tract. Further investigation is required on IFN-α2b to treat COVID-19.
Should give priority for clinical trials of Interferon Alpha-2b
The study is featured in the Canadian national newspaper – Globe and Mail in its May 13, edition under the article title ‘Interferon emerges as a potential treatment for COVID-19’. A researcher at Toronto University Health Network – Dr. Eleanor Fish said the awareness about this drug to treat coronavirus is slow and should give priority for the clinical trials on a large scale.
Interferons to treat coronavirus infections
According to Fish, interferons provide the first line of defense against all the viruses. However, viruses like coronavirus have evolved to block the response of interferon. It necessitates the need for interferons to treat coronavirus infections.
The new drug of BetterLife Pharma overrides the inhibitory effects of COVID-19. Fish said that instead of developing a virus-specific antiviral every time, it is better to consider interferons for the treatment of viruses like coronavirus.
Interferons have already received the nod to treat viral infections several years back. It is now time to repropose them to treat moderate to severe virus infections. Therefore, a large clinical trial involving Interferon Alpha-2b on a cohort of patients further supports the research.
CEO of BetterLife Pharma, Ahmad Doroudian, said the company is pleased with the results of a recently concluded study in using Interferon Alpha-2b to treat COVID-19. The outcome supports BetterLife’s approach to treating coronavirus. Ahmad said he supports the view of Fish and further excited by the recent study results.
CV Sciences Inc (OTCMKTS:CVSI) Navigates Market Storms
Any company that faces the campaign of short sellers experiences hard times; especially the shareholders. In the recent months, CV Sciences Inc (OTCMKTS:CVSI) had a rough battle with the investors which badly bruised the share price. In an Aug. 30, 2018 press statement, the company gave an update to shareholders regarding the situation.
In the update, CV Sciences acknowledges the “malicious” intent of the short sellers. The company CEO, Joseph Dowling further explains that they are victims of “campaigns run by short sellers in order to depress our stock price, so they could make financial windfalls.”
The CEO further details that: “We are also aware that at least one such group has boasted on social media platforms about its financial returns since their release of misleading information regarding the Company’s patent prosecution and drug development efforts.”
In rebuttal, the CEO affirms that the company presents strong financial numbers and that this will go on in future. He adds that there is nothing different with the business model since it is solid. Joseph speaks out so strongly about the “manipulations” and offers his sympathy for the shareholders.
“We will continue to do everything in our control to bring this activity to a halt. In the months ahead, we look forward to reporting our operating results in this fast-growing industry and providing updates on our drug development efforts,” he says.
A product milestone for CV Sciences Inc (OTCMKTS:CVSI)
The run in with the short sellers did not dampen the company’s spirits. In under two weeks, the company announced a great milestone for one of its products. The PlusCBD Oil
Such a status is important to product sales and consumer confidence in the company. Concurring with the assessment, the CEO says:
“We are committed to building consumer confidence and trust in the safety and quality of our products, supported by scientific evidence.
Tilray (TLRY) Joins Cannabis Sector’s Pause, Which Is Good News For People Who Missed Its July IPO
With the high-flying cannabis sector taking a pause, now is the time for investors to reassess their positions.
A good place to start would be by taking a moment to examine who is guiding cannabis-focused companies. In other words, who is it that is forming a company’s reputation.
Take, for example, high-flying Tilray, Inc. (TLRY). It’s a pioneer in medical cannabis research, cultivation, processing, and distribution. Now it is rapidly staking a strong place in Canada’s soon-to-be legal adult marijuana market.
Looking beyond its world-class research teams, investors will discover Tilray has one of the sector’s most prestigious board of directors.
Tilray’s board includes Rebekah Doop, who is a principal at Google. Then there’s Scotty Greenwood, who was chief of staff sat the U.S. Embassy in Canada, and is now the CEO of the Canadian American Business Council.
Of course, the board itself is not solely responsible for the 400 percent run up since Tilray’s July IPO. Still, it should comfort investors to know Tilray is in such good hands.
Doop and Greenwood are joined on the board by other corporate heavyweights, such as Christine St. Claire, who was a principal and lead audit partner at KPMG; Michael Auerbach, a risk expert who has held senior positions at the Center for American Progress and The Century Foundation, where he concentrated on issues related to U.S. Foreign Policy, National Security, and Conflict Resolution.
Rapid Expansion Into Legalized Pot
Based in British Columbia, Canada, Tilray is global concern. It is the only GMP-certified medical cannabis producer to supply cannabis flower and extract products to tens of thousands of patients, physicians, pharmacies, hospitals, governments, and researchers in 11 countries on five continents.
It’s also perfectly positioned in the heart of Canada’s legalized cannabis industry.
The Prince Edward Island Cannabis Management Corporation recently selected a Tilray subsidiary to supply its adult-use cannabis.
The purchase order will allow its wholly owned affiliate, The High Park Company, to supply PEI’s four cannabis stores and online channels with cannabis products. It’s all in anticipation of the launch of the adult-use market on October 17, 2018.
In all, Tilray has signed agreements to supply adult-use cannabis to consumers in seven Canadian provinces and territories, including British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, the Yukon territory, and the Northwest Territories
Its subsidiary, High Park, is Toronto-based, and is led by a team with deep experience in cannabis and global consumer brands.
Tilray established High Park in order to develop, sell, and distribute a broad-based portfolio of adult-use cannabis brands and products. Its portfolio is uniquely crafted and grown by master horticulturists dedicated to sustainable growing practices.
Tilray’s shares were downgraded Northland Capital, which gave “complex valuations” as the basis of its esoteric reasoning. Tilray’s share price shed nearly 11 percent on the news.
But Tilray is a strong company.
It has a partnership to develop medical products with Sandoz Canada, a division of Novartis (NVS). Tilray also has a relationship with Privateer Holdings and marijuana information website Leafly, along with distribution deals with Shoppers Drug Mart, Pharmasave and various Canadian provinces.
It is perfectly posi